Previous 10 | Next 10 |
Xenetic Biosciences (NASDAQ: XBIO ): FY GAAP EPS of -$6.33 misses by $0.77 . More news on: Xenetic Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-Company continues to advance preclinical development of its XCART™ CAR T therapy platform - - Expands XCART resources by adding expertise in cell therapy translational science and CMC - - Cash on hand expected to fund operations through mid-2021 - FRAMINGHAM, MA / ACCESSW...
FRAMINGHAM, MA / ACCESSWIRE / February 27, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, a...
- Dr. MacMichael brings over 35 years of experience in development and manufacture of therapeutic proteins, vaccines, and cell and gene therapies - - Dr. MacMichael to play key role in guiding cell therapy CMC to advance XCART™ Platform - FRAMINGHAM, MA / ACCESSWIRE / February...
Leading research expert in developing new therapeutic tools to treat hematologic malignancies and solid tumors using adoptive cell therapy Dr. Mamonkin is a faculty member in the Center for Cell and Gene Therapy at Baylor College of Medicine FRAMINGHAM, MA / ACCESSWIRE / February 13, 2...
Presentation on Tuesday, February 18 th 2020 at 2:30 p.m. ET FRAMINGHAM, MA / ACCESSWIRE / February 11, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform techno...
Nano cap Xenetic Biosciences ( XBIO -4.5% ) slips on almost double normal volume on the heels of results from a Phase 1/2 clinical trial sponsored by licensee Takeda (Shire's Baxalta) evaluating SHP656 (PSA-recombinant Factor VIII) in hemophilia A patients. The data were just published i...
- SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data commensurate with the profile of an extended half-life rFVIII product FRAMINGHA...
- Company ramps up activities to execute XCART's preclinical and regulatory strategy - - Cash runway expected to fund Company through preclinical advancements towards IND filing - FRAMINGHAM, MA / ACCESSWIRE / November 15, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or...
FRAMINGHAM, MA / ACCESSWIRE / October 29, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell ("CAR T") platform technology engineered to target patient-specif...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...